雪榕生物涨2.18%，成交额8426.43万元，主力资金净流入36.59万元

Company Overview - Shanghai Xuerong Biotechnology Co., Ltd. is located at 1487 Huifeng West Road, Fengxian District, Shanghai, established on December 8, 1997, and listed on May 4, 2016 [1] - The company's main business involves the research and development, cultivation, and sales of edible mushrooms, with revenue composition as follows: Enoki mushrooms 73.31%, King oyster mushrooms 22.27%, others 1.65%, supplementary 1.58%, and culture medium 1.19% [1] Stock Performance - On September 25, Xuerong Biotechnology's stock rose by 2.18%, reaching 6.08 CNY per share, with a trading volume of 84.26 million CNY and a turnover rate of 2.75%, resulting in a total market capitalization of 3.634 billion CNY [1] - Year-to-date, the stock price has increased by 75.22%, with a 3.93% rise over the last five trading days, a 3.65% decline over the last 20 days, and an 8.02% decline over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on May 20, where it recorded a net purchase of 57.18 million CNY [1] Financial Performance - For the first half of 2025, Xuerong Biotechnology reported operating revenue of 791 million CNY, a year-on-year decrease of 26.17%, and a net profit attributable to the parent company of -103 million CNY, a year-on-year increase of 28.58% [2] - The company has distributed a total of 236 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of June 30, the number of shareholders for Xuerong Biotechnology was 30,200, a decrease of 14.57% from the previous period, while the average circulating shares per person increased by 28.64% to 17,119 shares [2] Industry Classification - Xuerong Biotechnology belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the planting industry focused on edible mushrooms [2] - The company is associated with several concept sectors, including NMN concept, small-cap, low-price, biopharmaceuticals, and rural revitalization [2]